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Abstract
Objective: Centralized adiposity, insulin resistance, excess iron, and elevated oxidative stress place postmenopausal
women at risk for atherosclerotic cardiovascular disease (CVD). The objective of this study was to determine the
relationship among excess iron, oxidative stress, and centralized fat mass in healthy postmenopausal women.
Methods: The parent project recruited healthy women for a randomized, double-blind, clinical trial designed to
examine the effect of soy isoflavones on bone. At baseline (n¼ 122), we measured three antioxidant enzymes,
iron status indices (serum ferritin among others), oxidative stress indices (oxidized low-density lipoprotein
[oxLDL], urinary isoprostanes [PGF2a], protein carbonyls, DNA damage), and waist, hip, and thigh fat mass
using dual-energy x-ray absorptiometry (DXA). We calculated insulin resistance using the homeostasis model
assessment (HOMA). Multiple regression analysis was used to determine the CVD risk factors that contributed
to oxidative stress and centralized fat mass (waistþhip=thigh¼AndGynFM ratio).
Results: Almost 14% ( p< 0.0005) of the variability in oxLDL was accounted for by AndGynFM ratio (6.1%,
p< 0.0005), age (4.0%, p¼ 0.012), and serum iron (2.8%, p¼ 0.053). Similarly, 16% ( p< 0.0001) of the variability in
PGF2a was accounted for by the AndGynFM ratio (4.8%, p¼ 0.011), HOMA (3.9%, p¼ 0.021), and serum iron
(2.7%, p¼ 0.054). We accounted for 33% ( p 0.0001) of the variability in AndGynFM ratio by high-density
lipoprotein cholesterol (HDL-C) (4.3%, p¼ 0.008), ferritin (4.9%, p¼ 0.005), HOMA (4.5%, p¼ 0.006), oxLDL
(2.6%, p¼ 0.04), and PGF2a (3.0%, p¼ 0.025).
Conclusions: Our study suggests that reducing centralized fat mass and maintaining a favorable lipid profile,
antioxidant status, and iron status all may be important in protecting postmenopausal women from athero-
sclerotic CVD.
Introduction
Oxidative stress, body iron stores, blood lipids, andbody fat typically increase with age, especially after
menopause, because of the loss of endogenous estrogen pro-
duction. Oxidative stress or compromised antioxidant status
is thought to be involved in the etiology of diseases, including
cancer, atherosclerotic cardiovascular disease (CVD), and
cataracts, as well as the aging process.1 Favorable oxidative
status is defined as a balance between reactive oxygen species
(ROS) and the antioxidant defense system. Iron through free
radicals causes oxidation of lipids and proteins, contribut-
ing to atherosclerosis or vasoconstriction by promoting oxi-
dized low-density lipoprotein (oxLDL) and by promoting
isoprostanes.2 The cessation of menses contributes to a gen-
eral increase in body iron, translating into elevated serum
ferritin,3 as evidenced by 3-fold greater ferritin in postmeno-
pausal compared with premenopausal women.4 Although
controversial,5–7 some epidemiological studies show a posi-
tive relationship between body iron stores and atherosclerotic
CVD risk.8,9 Elevated ferritin concentration in postmeno-
pausal women was associated with an increased risk of is-
chemic stroke,9,10 possibly due to the interaction of other CVD
risk factors, particularly adiposity, that accelerate atherogen-
esis by stimulating oxidative stress.
Some studies do not support the role of iron in oxidative
stress. Iron supplementation did not increase oxLDL,11,12 and
body iron stores were not related to coronary heart disease
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(CHD) or oxLDL.13 However, women with high iron stores
and elevated total cholesterol (TC) were shown to be at
greater risk for carotid atherosclerosis than those with only
elevated iron stores.14 Thus, in a healthy population, iron
excess may not be a major concern; however, in persons with
high oxidative stress, hyperlipidemia, and centralized adi-
posity, iron excess may place them at greater CVD risk.15,16
The hypothesis that elevated iron stores are causally linked to
CVD17 suggests that oxidative imbalance is the central bio-
logical mechanism for the greater incidence of heart disease in
postmenopausal compared with premenopausal women.
Research is limited on the relationship among excess iron,
oxidative stress, and body fat distribution, despite the inde-
pendent association of each factor with CVD risk. A positive
association between serum ferritin and indices of central ad-
iposity,16,18 insulin resistance,19,20 and metabolic syndrome21
suggests a role of excess iron in obesity and CVD. The ob-
jective of our study was to determine the relationship among
atherosclerotic CVD risk factors, particularly oxidative stress
indices, centralized fat mass, and body iron status in healthy,
nonobese postmenopausal women.
Subjects and Methods
Study design
Postmenopausal women were recruited for the Soy Iso-
flavones for Reducing Bone Loss (SIRBL) clinical trial, a ran-
domized, double-blind, 3-year intervention that was designed
to examine the effects of two doses of soy isoflavones on bone
loss in postmenopausal women. The aim of this ancillary
study was to determine the relationship among specific ath-
erosclerotic CVD risk factors at baseline, including body iron
stores, oxidative stress, and centralized fat mass. The study
protocol, consent form, and subject-related materials were
approved by the Institutional Review Board (IRB) at ISU.
Approval for the dual-energy x-ray absorptiometry (DXA)
procedure was obtained from our institution’s IRB and ap-
propriate safety board. We obtained informed consent from
all women at the start of prebaseline screening.
Subject selection
We recruited subjects throughout the state of Iowa pri-
marily through direct mailing, stories in local newspapers,
regional radio advertisements, and other recruiting avenues
(Fig. 1). Telephone interviews (n¼ 2411) were conducted to
ensure that women met inclusion=exclusion criteria: post-
menopausal women65 years of age, cessation ofmenses (1
but 8 years), body mass index (BMI) (kg=m2) ranging
from18.5 through 29.9. We excluded vegans, smokers, and
high alcohol consumers (>7 servings=week). Based on amedi-
cal history questionnaire and blood chemistry profile, we also
excluded women with bone disease or any other chronic
disease and those womenwho had a first-degree relative with
breast cancer. We also excludedwomenwho chronically used
medications, such as cholesterol-lowering or antihypertensive
medications, oral or topical hormone or estrogen therapy,
selective estrogen receptor modulators, calcitonin, frequent
use of antibiotics, or any previous use of bisphosphonates.
Data collection
At baseline, we obtained from each subject a health and
medical history and a nutrition history using interviewer-
administered questionnaires. We assessed usual dietary in-
take using a food frequency questionnaire (FFQ) from Block
Dietary Data Systems (Berkeley, CA). Fasted blood samples
were drawn between 7 and 8 am and processed as serum,
plasma, and erythrocyte samples. We separated serum and
plasma from whole blood by centrifuging for 15 minutes at
48C at 1000g and stored aliquots at808C until analyses. Each
subject collected a 24-hour urine sample; we measured total
volume and froze aliquots at 208C until analysis. A certified
clinical reference laboratory (Laboratory Corporation of
America, Kansas City, MO) analyzed each subject’s serum
for the blood lipid profile (TC, LDL cholesterol [LDL-C],
high-density lipoprotein cholesterol [HDL-C], triacylgly-
cerol [TG]) and other blood chemistry markers. We mea-
sured oxidative stress indices (protein carbonyls, oxLDL,
urinary isoprostanes, specifically 15-isoprostane F2a [PGF2a],
Completed telephone screening = 2,411 
Completed pre-baseline screening = 241 
Enrolled, completed baseline testing = 122 Excluded = 119 
FIG. 1. Subject enrollment flow chart.
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8-hydroxy-20-deoxyguanosine [8-OHdG]), antioxidant en-
zymes (catalase, glutathione peroxidase [GPX], superoxide
dismutase [SOD]), insulin, and serum ferritin in the laboratory
at Iowa State University. We calculated the percentage in-
traassay and interassay coefficient of variation (CV) for each
method using a pooled sample as a quality control. The in-
traassay CV (%) was 2.5, 4.8, 3.2, and 2.5, and the interassay
CV (%) was 3.4, 5.2, 17, and 3.2, for protein carbonyls, oxLDL,
PGF2a, and 8-OHdG, respectively. The intraassay CV (%) was
5.3, 4.0, 8.7, and 4.9, and the interassay CV (%) was 8.4, 7.5,
10.9, and 5.6, for catalase, GPX, SOD, and ferritin, respectively.
We used erythrocyte lysate to measure antioxidant en-
zyme (catalase, GPX, SOD) activity and plasma to determine
protein carbonyls (per mg creatinine) (Cayman Chemical
Company, Ann Arbor, MI) and oxLDL (ALPCO Diagnostics,
Windham, NH). We determined urinary PGF2a (Oxford
Biomedical Research, Oxford, MI) using enzyme-linked im-
munoassay (ELISA) kits. Urine is better than blood to quantify
PGF2a because some factors, such as aspirin, may suppress the
circulating concentration,22 and urine is more stable than
blood. Wemeasured urinary 8-OHdG to assess DNA damage
using an ELISA kit (Stressgen Bioreagents, Victoria, BC, Ca-
nada). We measured serum ferritin to determine iron stores
using a radioimmunoassay (RIA) kit (Ramco Diagnostics,
Stafford, TX). Fasting insulin was measured using an RIA kit
(LINCO Research, St. Charles, MO), and the homeostatic
model assessment (HOMA) of insulin resistance for each
subject was calculated using the following formula.23
Fasting serum insulin (lU=mL)
· fasting plasma glucose (mg=dL)=405
A trained anthropometrist measured standing height and
weight; waist circumference and sagittal diameter (Holtain-
Kahn abdominal caliper, Crosswell, Crymych Dyfed, U.K.)
and these were used as anthropometric indices of centralized
adiposity. Sagittal diameter was measured at the narrowest
section between the small of the back and the navel, with
subjects relaxed in the supine position. Centralized adiposity
was also assessed using DXA (Delphi W Hologic Inc, Wal-
tham, MA) by a certified DXA operator who conducted a
whole body scan on each subject. One evaluator sectioned
each whole body DXA scan into waist, hip, and thigh regions
based on bone landmarks,24,25 and these subregions were
analyzed using special software (Discovery Version 12.3:7).
The androidal=gynoidal fat mass (AndGynFM) ratio was
calculated for each subject:
Waistþhip fat mass=thigh fat mass
Statistical analysis
Statistical analyses were performed with SAS (version 9.0,
Cary, NC), with p< 0.05 as the level of significance for all
analyses. Descriptive statistics included medians and range
for these data, as most were not normally distributed. Pearson
correlation analysis was used initially to examine the corre-
lations (data not shown) among the atherosclerotic CVD risk
factors (oxidative stress, antioxidant status, iron status, and
centralized adiposity). Classes of variables in modeling the
outcomes of interest (oxidative stress indicators and central-
ized adiposity) included all covariates that were biologically
plausible or significantly related based on the Pearson corre-
lation analysis. Multiple regression analysis with backward
selection was used to determine the CVD risk factors that
contributed to oxidative stress and centralized fat mass in
these healthy postmenopausal women.
Results
Subject characteristics
The subjects’ descriptive characteristics and daily nutrient
intakes at baseline are shown in Table 1. The median age of
subjects was 55 years, and time since menopause was 2.7
years. The BMI of women ranged from normal to over-
weight, and 47% had a BMI >25.0 kg=m2. Median dietary
intake of macronutrients and selected antioxidant nutrients
(vitamins A, C, E, and selenium) for these women was within
their dietary recommended intakes (DRIs). Great variability
was noted in dietary intake, as reflected by extrememinimum
and maximum values, a common limitation of memory-
dependent methods of assessment. Descriptive data for adi-
posity indices, oxidative stress indices, antioxidant enzymes,
iron status indices, blood lipid profile, glucose and insulin
concentrations, and insulin resistance (HOMA) are presented
in Table 2.
Oxidative status
The median values for the oxidative stress and antioxidant
status indices were within the normal range, based on the
manufacturer’s assay guidelines. Because the normal range is
not firmly established, we cannot determine the proportion of
women with abnormal values. There was a wide range (4- to
7-fold) of antioxidant enzyme activity (catalase, SOD, GPX)
Table 1. Subject Characteristics (n¼ 122)
Measurement Mediana
Range
(minimum–maximum)
Age (years) 55.2 (47.3–61.8)
Time since menopause
(years)
2.7 (1.0–7.9)
Weight (kg) 68.1 (47.8–89.2)
Height (cm) 165.6 (150.6–178.4)
BMI (kg=m2) 24.9 (18.9–29.8)
Dietary intake=dayb
Energy (KJ) 6649 (1771–19109)
Protein (g) 64 (20–168)
Carbohydrate (g) 195 (33–476)
Total fat (g) 67 (17–247)
Saturated fat (g) 20 (5–65)
Polyunsaturated fatty
acids (g)
16.1 (2.5–70.4)
Iron (mg) 11.4 (3.1–45.6)
Vitamin A (RE) 1286 (360–5163)
Vitamin C (mg) 100 (19–325)
Vitamin E (mg) 9 (2–38)
Selenium (mg) 75 (23–227)
aMedian values are reported for subject characteristics and dietary
intake, as most were not normally distributed.
bDietary intake was assessed using a food frequency questionnaire
(Block Dietary Data Systems).
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among the subjects, particularly for catalase and SOD. Simi-
larly, the oxidative stress indices (oxLDL, PGF2a, 8-OHdG,
protein carbonyls) varied widely (4- to 100-fold) among sub-
jects, being particularly high for protein carbonyls.
Iron indices
Median values for ferritin, hemoglobin (Hb), serum iron,
and transferrin saturation were within the normal range,
suggesting that these women did not have iron excess.
However, a small percentage (3%) of women had ferritin
values>140 ng=mL, and 9% had transferrin saturation<15%.
Only 1 woman had anemia, as indicated by Hb¼ 11.4 g=dL.
Adiposity and insulin resistance
Only 7.4% ofwomen hadwaist circumference values above
the cutoff (88 cm); thus, the majority of these women were not
considered at high risk of chronic diseases.26 Although the
median fasting insulin was within normal limits, it varied
almost 10-fold, whereas the glucose concentration did not
vary widely. Four of 122 women had an insulin concentration
>20mU=mL, and 8 had a glucose concentration>100mg=dL,
but these values were not in the diabetic range. The calculated
HOMA values ranged from 0.83 to 10.8.
Contributors to oxidative stress
and centralized fat mass
Multiple regression analysis was performed to examine the
potential contributors to lipid peroxidation and centralized fat
mass (Tables 3 and 4). The following variables were included
in both the oxLDL and PGF2amodels: age, ferritin, serum iron,
transferrin saturation, HOMA, intracellular antioxidants
(catalase, SOD, GPX), and dietary intake (vitamin E, vitamin
C, iron, energy). The variables included in the AndGynFM
ratio model were age, ferritin, serum iron, transferrin satura-
tion, HOMA, intracellular antioxidants (catalase, SOD, GPX,
oxLDL), oxidative stress indicators (protein carbonyls,
oxLDL, 8-OHdG), blood lipids (HDL-C and LDL-C), C-
reactive protein (CRP), and energy intake. Almost 14%
( p< 0.0005) of the overall variability in oxLDLwas accounted
for by the AndGynFM ratio (6.1%, p< 0.0005), age (4.0%,
p¼ 0.021), and serum iron (2.8%, p¼ 0.053). Similarly, 16%
( p< 0.0001) of the overall variability in PGF2a was explained
by the AndGynFM ratio (4.8%, p¼ 0.011), HOMA (3.9%,
p¼ 0.021), and serum iron (2.7%, p¼ 0.054). To determine the
contributing factors to centralized fat mass, we chose the ratio
of AndGynFM as the dependent variable because this ratio
emerged as a significant contributor in the oxidative stress
models and also provided a better model than the AndFM.
We accounted for 33% ( p 0.0001) of the overall variability in
the AndGynFM ratio by HDL-C (4.3%, p¼ 0.008), ferritin
(4.9%, p¼ 0.005), HOMA (4.5%, p¼ 0.006), oxLDL (2.6%,
p¼ 0.04), and PGF2a (3.0%, p¼ 0.025).
Discussion
Postmenopausal women are at increased risk of athero-
sclerotic CVD, which may be attributed to dyslipidemia, oxi-
dative stress, elevated iron stores, centralized adiposity,
insulin resistance, and other factors. We examined the re-
lationship of oxidative stress with circulating blood lipids,
iron, and obesity by including various markers of oxidative
damage related to lipid, protein, and DNA. However, the
oxidative damage to lipids as indicated by oxLDL and PGF2a
were the only markers that emerged as significant contribu-
tors. This supports the idea that lipid damage is involved in
obesity and the pathogenesis of CVD, whereas oxidatively
modified DNA and proteins may be more involved in carci-
nogenesis27 and cataract formation,28 respectively. Although
we measured three indicators of antioxidant enzymes (cata-
lase, SOD, GPX), none of them accounted for the variability in
oxidative stress indicators. Perhaps this was because of the
Table 2. Baseline Descriptive Measurements (n¼ 122)
Measurement Mediana
Range
(minimum-
maximum)
Iron indices
Ferritin (ng=mL) 53.1 (4.8–175.1)
Hemoglobin (g=dL) 13.7 (11.4–16.0)
Hematocrit (%) 40.8 (33.5–47.6)
Serum iron (mg=dL) 80.0 (31.0–177.0)
Transferrin saturation (%) 24.0 (7.0–56.0)
Oxidative stress indices
Urinary isoprostanes
(ng=mL)
2.44 (1.26–5.82)
Oxidized LDL (U=L) 73.7 (31.8–130.6)
8-Hydroxy-20-
deoxyguanosine (ng=mL)
43.7 (14.5–194.8)
Protein carbonyls (nmol=mg
protein)
6.0 (0.06–67.7)
Antioxidant enzymesb
Catalase (nmol=min=mL) 41.3 (5.9–112.5)
Superoxide dismutase
(U=mL)
755.6 (27.3–1874.2)
Glutathione peroxidase
(nmol=min=mL)
188.5 (91.7–430.4)
Central adiposity indices
Waist circumference (cm)c 76.7 (62.8–98.6)
Sagittal diameter (cm)c 18.6 (14.4–24.8)
Waistþhip fat mass (kg)d 5.37 (1.09–10.1)
Thigh fat mass (kg)d 3.26 (2.44–8.97)
AndGynFM ratiod,e 1.00 (0.45–2.20)
Blood lipids=lipoproteins
Total cholesterol (TC)
(mg=dL)
205 (142–285)
Total triacylglycerides
(mg=dL)
81 (31–290)
LDL-C (mg=dL) 122 (62–173)
HDL-C (mg=dL) 69 (42–103)
TC=HDL-C ratio 3.0 (1.9–4.9)
Other
Fasting insulin (mU=mL) 12.8 (4.5–47.2)
Fasting glucose (mg=dL) 87.0 (66.0–108.0)
HOMA6 2.72 (0.83–10.8)
aMedian values are reported for baseline descriptive data, as most
were not normally distributed.
bData for 5 subjects are missing (n¼ 117) because of processing
errors of erythrocytes at the time of collection.
cAssessed by anthropometric measurements.
dAssessed by DXA.
eAndGynFM ratio, andriodal (waistþhip)=gynoidal (thigh) fat
mass ratio.
fHomeostasis model assessment of insulin resistance (HOMA)
calculated as follows: Fasting insulin (mU=mL)fasting glucose
(mg=dL)=405.23
798 CRIST ET AL.
tremendous variability in the antioxidant enzyme values in
these women.
Adipose tissue is highly metabolic, and abdominal fat in-
duces oxidative stress, which in turn has been shown to cause
insulin resistance in men.17 The previous study indicated that
circulating PGF2a was related to adiposity and insulin resis-
tance in men, with obese men having a higher concentration
than their nonobese counterparts. In both men and women, a
high waist circumference was associated with elevated
oxLDL, independent of BMI,29 illustrating that abdominal fat
mass may induce a greater degree of oxidative stress than
overall fat mass. The DXA-derived centralized fat mass (An-
dGynFM) is advantageous because it is specific for fat and
encompasses both internal and external fat, whereas waist
circumference reflects both fat and lean mass. Our results
support the idea that centralized adiposity was one of the key
factors related to both elevated oxLDL and PGF2a, with age
being important for oxLDL and HOMA for PGF2a. Our study
results support the observed relationship18 between HOMA
and lipid-related oxidative stress.
Interestingly, serum iron was positively related (albeit not
significantly) to both oxidative stress indices, suggesting that
high circulating ironmay induce oxidative stress based on the
role of iron in generating free radicals. Although the rela-
tionship is only suggestive, it does not support the previous
study showing an association between iron status and LDL
oxidative susceptibility in healthy men and women.11 Per-
haps the association between serum iron and oxLDL was not
striking in our study because the women were not markedly
hypercholesterolemic (LDL-C 160mg=dL), nor did they
have elevated iron stores (only 3 women had serum ferritin
>140 ng=mL); thus, they were not very susceptible to oxida-
tive damage.
A recent cross-sectional study, showing an association
between abdominal adiposity (waist girth and waist=hip ra-
tio) in young adults with early atherosclerosis as evidenced by
coronary artery calcification,30 suggests the importance of
centralized fat in predicting CHD. Hence, it is important to
determine the factors that contribute to centralized adiposity.
As expected, our study showed that ferritin, HOMA, HDL-C,
Table 3. Factors Related to Oxidative Stress (n¼ 122)a
oxLDLb: Overall model R2¼ 14.0% (Adj R2¼ 11.81%), F¼ 6.40 (p¼ 0.0005)c
Independent variable Parameter estimate Percentage varianced p value Variance inflation
Intercept 11.40 0.674
AndGynFM ratio 13.62 6.16 <0.0044 1.03
Age 1.135 4.00 0.021 1.03
Serum iron 0.103 2.79 0.053 1.00
PGF2a: Overall model R
2¼ 15.87% (Adj R2¼ 13.73%), F¼ 7.42 (p¼ 0.0001)e
Independent variable Parameter estimate Percentage varianced p value Variance inflation
Intercept 1.142 0.0012
AndGynFM ratio 0.617 4.81 0.011 1.19
HOMA 0.158 3.86 0.021 1.21
Serum iron 0.005 2.71 0.054 1.02
aMultiple regression analysis with stepwise selection.
boxLDL, oxidized low-density lipoproteins; PGF2a, urinary isoprostanes; AndGynFM ratio, androidal (waistþhip)=gynoidal (thigh) fat
mass ratio; HOMA, homeostasis model assessment of insulin resistance.
cVariables eliminated ( p> 0.10): age, serum ferritin, transferrin saturation, HOMA, intracellular antioxidants (catalase, SOD, GPX), dietary
antioxidants (vitamins E and C), iron, energy intake.
dSquared semipartial type II correlation coefficient, which accounts for shared variance among variables.
eVariables eliminated ( p> 0.10): age, serum ferritin, total cholesterol, intracellular antioxidants (catalase, SOD, GPX), dietary antioxidants
(vitamins E and C), iron, and energy intake.
Table 4. Factors Related to Central Adiposity (n¼ 122)a
AndGynFM ratiob: Overall model R2¼ 32.67% (Adj R2¼ 29.76%), F¼ 11.25 (p 0.0001)c
Independent variable Parameter estimate Percentage varianced p value Variance inflation
Intercept 0.697 0.0005
Serum ferritin 0.002 4.90 0.004 1.02
HOMA 0.066 4.52 0.006 1.21
HDL-C 0.005 4.27 0.008 1.21
PGF2a 0.072 3.02 0.024 1.14
OxLDL 0.003 2.62 0.035 1.06
aMultiple regression analysis with backward selection.
bAndGynFM ratio, androidal (waistþhip)=gynoidal (thigh) fat mass ratio; HOMA, homeostasis model assessment of insulin resistance;
PGF2a, urinary isoprostanes; oxLDL, oxidized LDL.
cVariables eliminated ( p> 0.10): age, serum iron, intracellular antioxidants (catalase, SOD, GPX), oxidative stress indicators (protein
carbonyls, oxLDL, 8-OHdG), CRP, energy intake.
dSquared semipartial type II correlation coefficient, which accounts for shared variance among variables.
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PGF2a, and oxLDL contributed to centralized fat mass
(Table 4) (AndGynFM ratio). As centralized adiposity is a
well-known risk factor for atherosclerotic CVD, the associa-
tion of ferritin with centralized fat mass suggested a role for
iron in androidal fat accumulation. Perhaps excess iron ex-
acerbates centralized adiposity by aggravating insulin resis-
tance,16,31 but it is also possible that centralized adiposity may
contribute to elevated ferritin. As an acute-phase protein,
ferritin may be elevated in inflammatory conditions, other
than excess body iron. Overweight and obese individuals are
characterized by low-grade inflammation.32 Thus, increased
ferritin may reflect obesity-induced inflammation, a relatively
new factor in the etiology of atherosclerotic CVD, with ele-
vations placing postmenopausal women at increased risk of
ischemic stroke.9 Our results are contrary to the NHANES III
findings that the prevalence of iron deficiency is higher in
obese children.33 Obesity has been shown to be negatively
associated with circulating iron in younger groups due to the
inflammatory response34; however, we did not find this as-
sociation between adiposity and indicators of circulating iron
in our postmenopausal women. As CRP and serum iron were
not significant contributors to central adiposity, our results
suggest that the relationship between adiposity and ferritin
may not be a result of inflammation in these postmenopausal
women. Differences in findings may be attributed to the cri-
terion that subjects in our study were not obese and were also
not at risk for developing iron deficiency. Hence, obesity-
induced iron deficiency and iron excess may be of concern,
and consequences may be different in younger vs. older in-
dividuals.
Our results are supported by data indicating a direct rela-
tion between elevated ferritin and visceral and subcutaneous
fat, using computed tomography (CT).20 Although a meta-
analysis showed no significant association between excess
iron stores and CHD,7 other studies have reported such an
association.8,9 The Bruneck study14 reported ferritin as one
of the strongest indicators of carotid artery disease. The role
of iron in CVD also may be mediated through induced
insulin resistance,19 thus increasing centralized adiposity.
The median ferritin concentration was 2-fold higher (86 vs.
42 ng=mL) in metabolic syndrome patients with insulin re-
sistance (defined by HOMA) compared with patients without
insulin resistance,31 andwaist circumferencewas significantly
higher in women with elevated ferritin (>75 ng=mL). Al-
though we did not find a significant relationship between
HOMA and ferritin (data not shown), there is evidence that
excess iron may lead to insulin resistance.35,36
HOMA is a useful tool to assess insulin resistance because it
takes both circulating glucose and insulin into account. Al-
though the subjects in our study were deemed healthy, we
found that centralized fat mass was positively associated with
HOMA and oxidative stress and negatively associated with
HDL-C. Central adiposity has been linked not only to insulin
resistance and oxidative stress but also to dyslipidemia, spe-
cifically low HDL-C and high LDL-C. In a cross-sectional
study with healthy men and women (n¼ 20,021),37 research-
ers reported that thewaist=hip ratio, independent of BMI, was
positively associated with LDL-C and negatively associated
with HDL-C. Similar results were published from another
cross-sectional study,38 although the association between
LDL-C and waist circumference, once adjusted for age and
BMI, was significant only in men.
Oxidative stress has been shown to be responsible for en-
dothelial dysfunction, an early event in atherosclerosis.39 The
PGF2a concentration was reported to be significantly higher in
obese compared with nonobese men.18 Circulating lipids in
humans were susceptible to oxidative damage with general-
ized obesity,40 and body weight and waist circumference
were significantly related to oxLDL after adjusting for lifestyle
and CVD risk factors.29 Similar to previous studies,29,40 our
results showed that lipid oxidation indicators, but not anti-
oxidant status or protein (protein carbonyls) and DNA (8-
OHdG) damage indicators, were positively associated with
centralized adiposity in these women.
Conclusions
We demonstrated an association among oxidative stress,
iron status, lipids, insulin resistance, and centralized adipos-
ity. Iron status was positively associated with centralized
adiposity, possibly mediating insulin resistance or oxidative
stress in these postmenopausal women. Although this is an
observational study, reducing centralized fat mass and
maintaining a favorable lipid profile, antioxidant status, and
iron status all may be important in protecting postmeno-
pausal women from atherosclerotic CVD. Further studies
should elucidate the purported mechanism by which iron
status might influence centralized adiposity and insulin
resistance.
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